174 320
Financial disclosures:
Christian P. Meyer certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents filed, received, or pending), are the following: None.
Funding/Support and role of the sponsor:
This study was funded in part
by the Trust family, Loker Pinard, and Michael Brigham Funds for
Kidney Cancer Research (to Toni K. Choueiri) at Dana-Farber Cancer
Institute, the Dana-Farber/Harvard Cancer Center Kidney Cancer
Program, and the Dana-Farber/Harvard Cancer Center Kidney Cancer
(SPORE P50 CA101942-01).
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/ j.eururo.2017.03.005 .References
[1]
Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 2011;185:439–44.[2]
Bartlett EK, Simmons KD, Wachtel H, et al. The rise in metastasect- omy across cancer types over the past decade. Cancer 2015;121: 747–57.[3]
Hatzaras I, Gleisner AL, Pulitano C, et al. A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB 2012;14:532–8.
[4]
Kudelin N, Bolukbas S, Eberlein M, Schirren J. Metastasectomy with standardized lymph node dissection for metastatic renal cell carci- noma: an 11-year single-center experience. Ann Thorac Surg 2013;96:265–70, discussion 70-1.
[5]
van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: a multicenter retro- spective analysis. Eur Urol 1999;35:197–203.
[6]
Chapin BF, Delacroix Jr SE, Culp SH, et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 2011;60:964–71.
[7]
Meyer CP, Hollis M, Cole AP, et al. Complications following common inpatient urological procedures: temporal trend analysis from 2000 to 2010. Eur Urol Focus 2015;2:3.
[8]
Joyce DD, Psutka SP, Groeschl RT, et al. Complications and outcomes associated with surgical management of renal cell carcinoma in- volving the liver: a matched cohort study. Urology 2017;99:155–61.[9]
Sun M, Abdollah F, Shariat SF, et al. Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: a national series. Eur J Surg Oncol 2012;38:80–7.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 1 7 1 – 1 7 4
174